The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
Open accessAbstract
Objective: To determine the safety of rituximab, to provide preliminary data regarding the potential efficacy of rituximab, and to investigate the effects of rituximab on autoimmunity and fibrosis in patients with diffuse cutaneous systemic sclerosis (dcSSc). Methods: Fifteen patients with dcSSc, all of whom experienced their first non–Raynaud's disease–associated disease manifestation within 18 months of trial entry, were recruited to receive 2 intravenous doses of rituximab (1,000 mg), administered 2 weeks apart. Safety, clinical, and exploratory outcomes were evaluated at baseline and at 6 months. The primary outcome was the change in the modified Rodnan skin thickness score (MRSS) at 6 months compared with baseline. Results: Adverse events included frequent infusion reactions and rare infections (urinary tract infection and dental abscess occurred in 1 patient each). The mean change in the MRSS between baseline and 6 months was not significant. Results of pulmonary function tests and other measures of major organ involvement were stable. The modest B cell infiltrates that were present in most skin biopsy specimens at baseline were completely depleted at 6 months in most patients. Autoantibody titers showed only modest and variable changes after treatment. Conclusion: In this pilot study, treatment with rituximab appeared to be safe and well tolerated among patients with dcSSc. Rituximab treatment resulted in both depletion of circulating B cells and depletion of dermal B cells but had little effect on the levels of SSc‐associated autoantibodies. Rituximab treatment did not appear to result in a significant beneficial effect on skin disease. The potential efficacy of rituximab in other organs such as the lung could not be clearly evaluated in this small open‐label trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationClements, P. J., Lachenbruch, P. A., Siebold, J., White, B., Weiner, S. J., Martin, R. W., Weinstein, A., Weisman, M. H., Mayes, M. D., & Collier, D. H. (1995) · PubMed · Cited by 874
Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis
Svegliati Baroni, S., Santillo, M., Bevilacqua, F., Luchetti, M., Spadoni, T., Mancini, M., Fraticelli, P., Sambo, P., Funaro, A., Kazlauskas, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052955 · Cited by 585
Steen, V. D., & Medsger, T. A. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401110 · Cited by 504
Denton (2007) · doi:10.1002/art.22289 · Cited by 447
Systemic and cell type-specific gene expression patterns in scleroderma skin
Whitfield, M. L., Finlay, D. R., Murray, J. I., Troyanskaya, O. G., Chi, J.-T., Pergamenschikov, A., McCalmont, T. H., Brown, P. O., Botstein, D., & Connolly, M. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635114100 · Cited by 409
Clements, P. J., Furst, D. E., Wong, W.-K., Mayes, M., White, B., Wigley, F., Weisman, M. H., Barr, W., Moreland, L. W., Medsger Jr., T. A., et al. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1194::aid-anr16>3.0.co;2-7 · Cited by 330
Seibold, J. R., Korn, J. H., Simms, R., Clements, P. J., Moreland, L. W., Mayes, M. D., Furst, D. E., Rothfield, N., Steen, V., Weisman, M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-11-200006060-00004 · Cited by 273
Self-citationSaito, E., Fujimoto, M., Hasegawa, M., Komura, K., Hamaguchi, Y., Kaburagi, Y., Nagaoka, T., Takehara, K., Tedder, T. F., & Sato, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15078 · Cited by 225
Cited by
The Dynamics of the Skin’s Immune System
Nguyen, A. V., & Soulika, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081811 · Cited by 694
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationJordan, S., Distler, J. H. W., Maurer, B., Huscher, D., van Laar, J. M., Allanore, Y., Distler, O., Airo, P., Sancho, J. J. A., Ananjeva, L., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204522 · Cited by 434
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Daoussis, D., Liossis, S.-N. C., Tsamandas, A. C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Karampetsou, M., Yiannopoulos, G., & Andonopoulos, A. P. (2010) · Rheumatology · doi:10.1093/rheumatology/kep093 · Cited by 394
Metadata
- Authors
- Lafyatis, R., Kissin, E., York, M., Farina, G., Viger, K., Fritzler, M. J., Merkel, P. A., & Simms, R. W.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-01-29
- Volume
- 60
- Issue
- 2
- Pages
- 578-583
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2008227366
- Cited by
- 288
- References
- 17
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. https://app.cochat.ai/papers/10.1002/art.24249
- The paper
- Lafyatis, R., Kissin, E., York, M., Farina, G., Viger, K., Fritzler, M. J., Merkel, P. A., & Simms, R. W. (2009). B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis & Rheumatism. https://doi.org/10.1002/art.24249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.